Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump backs ‘immediate release’ of documents on FBI search of Mar-a-Lago
    • Luxury watch prices plummet on weak Chinese consumer confidence
    • Spain says gas link to wider EU could be ready within months
    • Trump under investigation for possible violation of US Espionage Act
    • Author Salman Rushdie stabbed at event in New York state
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Miami becomes the new boom town for corporate lawyers
      • The Qantas chief who brought a new travel disruption term to Australian vernacular
      • Scotch whisky shows surprising strength in global gloom
      • UK energy tax breaks are at odds with cost of living crisis
      • Mark Carney to become chair of Brookfield’s asset management spin-off
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • Live news updates from August 12: Trump under Espionage Act investigation, Salman Rushdie stabbed in western New York
      • Spain says gas link to wider EU could be ready within months
      • Asset managers bet big on crypto despite market rout
      • Glencore cuts ties with Chinese trader over missing $500mn of copper
      • Next financial crisis likely to centre on private markets
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Mortgage wake-up call for middle classes
      • Next financial crisis likely to centre on private markets
      • Western companies wake up to China risk
      • Russia’s diplomats are now reduced to propagandists
      • Companies are struggling to adjust as consumers go cold on goods
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Can a city be redesigned for the new world of work?
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Is the UK housing market at a turning point?
      • Formula 1’s Toto Wolff: ‘You need to push people out of their comfort zone’
      • How we live now: Afghanistan’s women speak
      • My handwriting is terrible. Should I be worried?
      • The hottest swimwear — influenced by cold water sport
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    Drugs research

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Saturday, 30 July, 2022
      AstraZeneca PLC
      AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

      Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

    • Tuesday, 19 July, 2022
      Special ReportFT Health Centre
      FT Health: Future of Antibiotics

      The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain

    • Tuesday, 19 July, 2022
      Special ReportFT Health: Future of Antibiotics
      Antibiotic resistance raises prospect of untreatable gonorrhoea

      Just one drug remains effective for the sexually transmitted disease but soon the bacteria may be able to evade it

    • Thursday, 14 July, 2022
      FT Magazine
      A new ‘miracle’ weight-loss drug really works — raising huge questions

      Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

    • Wednesday, 13 July, 2022
      Pfizer Inc
      Why Pfizer’s ‘living with Covid’ pill is not a miracle drug

      Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness

    • Monday, 27 June, 2022
      Covid-19 vaccines
      Pause in medication would improve Covid jab response for millions, study shows

      Short break in immune suppression treatment improves antibody production after vaccination while doing little harm

    • Tuesday, 14 June, 2022
      The Big Read
      BioNTech’s second act: can it transform the fight against cancer?

      The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven

    • Friday, 10 June, 2022
      Pharmaceuticals sector
      GSK hopes for boost from respiratory virus jab

      Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline

    • Wednesday, 8 June, 2022
      Quest for pill to stall Parkinson’s disease takes step forward

      Drug from Denali Therapeutics offers hope for sufferers of degenerative brain disorder

    • Wednesday, 8 June, 2022
      LexBioNTech
      BioNTech/pancreatic cancer: mRNA jabs may tame a savage disease Premium content

      German biotech’s promising early-stage results make it a sought-after partner

    • Wednesday, 1 June, 2022
      Indivior sees ‘huge opportunity’ for drug targeting cannabis misuse

      Biotech company hopes to win first US approval for medicine aimed at people addicted to marijuana

    • Thursday, 26 May, 2022
      Special ReportFT Health: Future of Antibiotics
      Vaccines hold potential to curb antibiotic resistance

      Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant

    • Monday, 9 May, 2022
      Covid-19 vaccines
      BioNTech beats forecasts on back of Covid vaccine demand

      German biotech maintains guidance but prepares for fall in sales because of jab oversupply

    • Friday, 29 April, 2022
      LexEli Lilly & Co
      Obesity treatments: hunger-suppressing drugs whet investors’ appetite Premium content

      On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets

    • Thursday, 28 April, 2022
      Eli Lilly says obesity drug has similar results to weight-loss surgery

      Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker

    • Tuesday, 26 April, 2022
      Special Report
      FT Health: Innovation in Healthcare

      The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy

    • Tuesday, 26 April, 2022
      Special ReportFT Health: Innovation in Healthcare
      Streamlined EU process promises faster access to breakthrough drugs

      ‘Intricate dance’ under way to ensure simplified assessments of new medicines maintain quality and integrity

    • Tuesday, 12 April, 2022
      Antibiotic resistance
      How will UK’s fixed-fee scheme for antibiotics help tackle the growing health crisis?

      Move could boost global development of drugs to ease antimicrobial resistance

    • Monday, 7 March, 2022
      Special ReportFT Health: Future of Antibiotics
      How pharma economics hold back antibiotic development

      New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say

    • Tuesday, 22 February, 2022
      Pharmaceuticals sector
      Nimble UK regulator is a draw for drugmakers, says former vaccines chief

      Kate Bingham urges fund managers to step up investment in life sciences

    • Friday, 28 January, 2022
      Sally Davies
      It’s time to confront the pandemic of antibiotic resistance

      To save lives and economies, we must make progress by drawing on lessons from Covid-19

    • Monday, 10 January, 2022
      Coronavirus treatment
      Novartis to seek speedy approval for Covid drug after positive trials

      Swiss drugmaker to license antiviral therapeutic after success in early-stage tests

    • Wednesday, 5 January, 2022
      Pfizer Inc
      Pfizer and BioNTech team up to develop mRNA-based shingles vaccine

      Drugmakers set to take on GSK as they aim to replicate Covid jab success

    • Tuesday, 4 January, 2022
      ExplainerCoronavirus pandemic
      Long Covid: why do some people have symptoms months after infection?

      Researchers say more than 100m suffer ill effects for at least 12 weeks

    • Thursday, 30 December, 2021
      UK life sciences lobby calls for investment in antivirals to fight Covid

      Lower effectiveness of vaccines against Omicron makes need for antivirals more urgent, says UK BioIndustry Association chair

    Previous page You are on page 1 Next page

    Topics related to Health & pharmaceuticals

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT LiveUS Pharma and Biotech SummitExploring new frontiers for business and for healthcare
    Tuesday, 16th May 2023United Kingdom
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In